Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease. (PubMed, Front Nephrol) - Oct 27, 2026 - "The recent development of potent Lp(a)-lowering drugs offers an exciting opportunity to effectively address residual risk in the general population and in patients with CKD. No data are yet available on their use in patients with CKD but pending future definition of their efficacy on cardiovascular outcomes, approval, dosing, and long-term safety, these drugs might possibly represent a useful tool for cardiovascular prevention in these patients."
Journal • Review • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Diabetes • Dyslipidemia • Glomerulonephritis • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • APOB
|
|
Antonio Vacca; Claudio Pagano; Cristiana Catena; Gabriele Brosolo; Jacopo Comand; Leonardo A Sechi; Luca Bulfone; Stefano Marcante
|